BSX RSI

What is BSX?

Founded in 1979 by John Abele and Pete Nicholas, Boston Scientific started with a mission to make less invasive medicine a reality. Based in Marlborough, Massachusetts, the company has grown from a small startup into a global med-tech powerhouse. Their business model focuses on high-growth markets within the healthcare sector, specifically targeting chronic conditions that require specialized medical devices.

The company operates across three main segments: MedSurg, Rhythm and Neuro, and Cardiovascular. You have likely heard of their core products like the Watchman device for stroke risk reduction in AFib patients. They also dominate in areas like interventional cardiology with stents and balloons, endoscopy for gastrointestinal issues, and neuromodulation for chronic pain management. They are constantly pushing the envelope with robotic-assisted technologies and minimally invasive tools that reduce hospital stays.

A major historical milestone was the 2004 acquisition of Guidant, which solidified their spot in the cardiac rhythm management space. More recently, their acquisition of Silk Road Medical shows they are still aggressive on the M&A front to bolster their portfolio. Financially, BSX is a standout in the sector, consistently delivering high-single-digit organic revenue growth and maintaining strong margins. They have a knack for identifying niche markets early and scaling them into billion-dollar franchises.

Looking ahead to 2026, the strategy is focused on category leadership. I expect them to lean heavily into the electrophysiology market with their FARAPULSE Pulsed Field Ablation system, which is a total game-changer for treating heart arrhythmias. By 2026, they should be seeing full-scale global adoption of this technology. They are also aiming to expand their footprint in emerging markets and further integrate AI-driven diagnostics into their device ecosystems to provide better patient outcomes while effectively lowering overall healthcare costs.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For BSX, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Boston Scientific Corp. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding BSX RSI Signals

• Oversold (RSI below 30): When BSX RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates BSX may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When BSX price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for BSX

This page displays both daily and weekly RSI for BSX. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Boston Scientific Corp.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when BSX RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Boston Scientific Corp. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.